Immunotherapy response results predicted from m6Ascore classification demonstrated that the predictive performance of the m6Ascore in NSCLC patients treated with drugs anti-PD1 and anti-CTLA4 reaches a meaningful result (AUC = 0.88). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.